Busca avançada
Ano de início
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Frequency and clinical relevance of anti-Mi-2 autoantibody in adult Brazilian patients with dermatomyositis

Texto completo
Cardoso dos Passos Carvalho, Maria Isabel [1] ; Shinjo, Samuel Katsuyuki [1, 2]
Número total de Autores: 2
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Fac Med FMUSP, Div Rheumatol, Sao Paulo - Brazil
[2] Univ Sao Paulo, Fac Med, Disciplina Reumatol, Av Dr Arnaldo 455, 3 Andar, Sala 3150, BR-01246903 Sao Paulo - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Citações Web of Science: 0

Abstract Background: To analyze the frequency and clinical relevance of anti-Mi-2 autoantibody in a representative sample of patients with dermatomyositis. Methods: This longitudinal inception cohort study, from 2001 to 2017, included 87 definite adult dermatomyositis. Anti-Mi-2 analysis was performed using a commercial kit. Results: Seventeen patients (19.5%) had anti-Mi-2 and 70 (80.5%) did not have this autoantibody. The following parameters were equally distributed between the patients with versus without anti-Mi-2: mean age at the disease diagnosis onset, median follow-up time, constitutional symptoms (baseline), cutaneous cumulative lesions, dysphagia, joint and pulmonary involvement. There was also no difference between the groups in relation to follow-up time, disease relapsing, treatment, disease status, deaths and occurrence of neoplasia. In contrast, patients with anti-Mi2 antibodies had higher frequency of elevated serum levels of muscle enzymes at disease onset (median: creatine phosphokinase 6240 [3800-9148] U/L and aldolase 60.0 [35.0-138.0] U/L), lower frequency of pulmonary involvement at disease onset (5.9%), less current glucocorticoid dose (median: 0 [0-10] mg/day), and higher frequency of disease remission during follow-up (58.8%) in comparison with patients without anti-Mi-2 autoantibody (484 [115-4880] and 12.1 [6.3-70.0] U/L, 40.0%, 0 [0-10] mg/day, 27.1%, respectively). Conclusion: The anti-Mi-2 autoantibody was found in one fifth of patients with dermatomyositis. This autoantibody was associated with a lower occurrence of pulmonary involvement, a higher frequency of disease in remission, and elevated levels of muscle enzymes. There was also no correlation regarding the frequency of disease relapsing or neoplasia development. (AU)

Processo FAPESP: 11/12700-1 - Perfil e prevalência de autoanticorpos miosite-específicos e miosite-associados na população brasileira com a dermatomiosite/polimiosite
Beneficiário:Samuel Katsuyuki Shinjo
Modalidade de apoio: Auxílio à Pesquisa - Regular